|Special sample requirements
Fully labelled and not haemolysed.
Sample must be handwritten.
||The sample tube should be transferred to the laboratory for storage between 2-8°C.
2 working days - NHSBT referrals take on average another 5 working days
The Antenatal Red Cell Screening Programme for the Prevention of Haemolytic Disease of the Fetus Newborn (HDFN) provides:
ABO and RhD type.
A screen for red cell alloantibodies - which comply with the relevant British Society for Haematology (BSH) guidelines and the Royal College of Obstetricians & Gynaecologist (RCOG) Green-top Guidelines.
The objectives of the screening programme are:
Identify RhD negative women who may need anti-D prophylaxis.
Supply a blood group card to all RhD negative women screened.
Detect and identify red cell antibodies which have the potential to cause HDFN.
Identify pregnancies at risk of HDFN due to maternal antibodies.
Simplify the pre-transfusion testing needed in providing blood urgently for obstetric emergencies.
Allow Planning of transfusion support for mothers with rare antibodies.
Please refer to Clinical Transfusion Team
LCL Transfusion laboratories are accredited to ISO 15189 by United Kingdom Accreditation Service (UKAS) for the clinical services they provide. They are also licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for the services that fall under the Blood Safety and Quality Regulations (BSQR).